Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co LtdfiledCriticalOtsuka Pharmaceutical Co Ltd
Priority to JP57202359ApriorityCriticalpatent/JPS5993019A/ja
Priority to EP83111446Aprioritypatent/EP0109653A3/en
Priority to US06/551,841prioritypatent/US4536391A/en
Priority to CA000441285Aprioritypatent/CA1212917A/en
Publication of JPS5993019ApublicationCriticalpatent/JPS5993019A/ja
Publication of JPH0249708B2publicationCriticalpatent/JPH0249708B2/ja
Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications
Thrombin derivatives and process for producing the same, anhydrothrombin derivatives and process for producing the same, platelet agglutination-inducing compositions, method of inducing platelet agglutination, clinical test reagents, clinical test method, thrombosis inhibitors, adsorbent and process for producing the same